Hariharan Easwaran
Has grant
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
High-efficiency microfluidic-assisted single-cell DNA methylome sequencing
Open Date: 2017-08-03
Close Date: 2020-07-30
Grant: Close
(PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer
Open Date: 2014-06-01
Close Date: 2018-05-31
Grant: Close
Evelyn Grollman Glick Scholar Award
Open Date:
Close Date:
Articles (21)
Year:
2026
Year:
2026
Proportion of methylated CpG sites in ovarian and mucinous carcinomas. The proportion of methylated CpG sites (mean Beta-values >0.3) are shown for patients with mucinous stomach, mucinous pancreatic, and ovarian mucinous and ovarian endometrioid carcinomas. Methylation was only available for one individual with colorectal mucinous carcinoma (not shown).
Year:
2025
Circos plots of ovarian endometrioid carcinoma samples. Circos plots depict copy number alterations (black line segments interior of the chromosomes) as well as intra- and inter-chromosomal rearrangements (blue lines that connect different portions of the cancer genome).
Year:
2025
Mutation signature analyses. (a) Mutation signatures for ovarian and uterine endometrioid carcinomas visualized with unsupervised clustering. (b) Mutation signatures for ovarian and GI mucinous carcinomas. The intensity of the heatmap colors indicates the percentage of the overall mutational profile for a sample that is explained by the mutation signature.
Year:
2025
Relationship between tumor purity and number of somatic mutations. (a) Tumor purity for multiple histological tumor types were estimated using FACETS. Samples that FACETS did not process due to undetectable copy number changes are marked with an x. (b) Patients with uterine endometrioid adenocarcinomas were more than twice as likely to have a hypermutator defect compared to patients with other cancers, including patients with ovarian endometrioid cancer (95% CI: 1.1 - 4.2-fold increase).
Year:
2025
Integrated genomic analyses of ovarian and colorectal mucinous cancers. Integrated analyses of somatic point mutations, structural variants, including linked amplicons, deletions, and rearrangements, organized by pathways. The top of the figure shows the number of each type of alteration, the middle portion reflects the alterations present in each sample for each gene and pathway, and the bottom shows the mutation spectra.
Year:
2025
WGS analyses of linked amplicons and rearrangements. A, Circos plots for linked amplicons for individual tumor samples with >100 structural variants. Circos plots depict copy number alterations as well as intra- and inter-chromosomal rearrangements. Segmented normalized estimates of read depth were used to identify candidate focal amplifications (teal) and focal deletions (red). Rearranged read pairs and split reads were used to identify inter- and intra-chromosomal rearrangements (blue). B, For linked amplicon graphs, nodes represent genes, node size represents the number of times the segment is represented in the genome, color indicates the chromosome location of the amplified segment, and edges denote segments that are connected in the rearranged cancer genome. Known driver genes indicated by triangles are often hubs in these networks, suggesting that amplification of these genes occurs early and can be connected to many of the other amplicons. C, Reads aligned to the fusion junction of two representative rearrangements. Split reads that span the fusion junction are shown in black, whereas read pairs that reside on either side of the junction are shown in green and blue, providing additional evidence for specific rearrangements.
Year:
2025
Integrated genomic analyses of ovarian and uterine endometrioid adenocarcinomas. Integrated analyses of somatic point mutations, structural variants, including linked amplicons, deletions, and rearrangements, organized by pathways. The top of the figure shows the number of each type of alteration, the middle portion reflects the alterations present in each sample for each gene and pathway, and the bottom shows the mutation spectra.
Year:
2025
Mutations in ESR1 at Tyr537 and Leu536. ESR1 mutations identified in two patients with uterine endometrioid carcinomas occurred at Tyr537, a hotspot most commonly associated with aromatase inhibitor resistance in patients with breast cancer patients, and Leu536. This hotspot is in close proximity to the region of the estrogen receptor that is important for ligand-dependent transcriptional function. The Tyr537 mutations cause a conformational change that constitutively activates the receptor independent of estrogen receptor binding. The Tyr537 residue is highlighted in blue in a three-dimensional view of the ESR1 protein (bottom). Due to its physical proximity to the Tyr537 hotspot, the Leu536 mutation is likely to have the same activating effect on the estrogen receptor.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2023
Collaborators (15)
Ernst Lengyel
University of Chicago
Wenbing Xie
Professor/Principal Investigator
University of Science and Technology of China
Nita Ahuja
Chair of Surgery
Yale University
Victor E. Velculescu
Assistant/Associate/Professor of Oncology and Pathology
Johns Hopkins University School of Medicine
Kathleen Burns
Professor and Department Chair
Dana-Farber Cancer Institute
Keith A. Crandall
Director
George Washington University
Matthew Bendall
Associate Research Professor
George Washington University
Hassan Fazilaty
Group leader
University Hospital of Zurich
Tian-Li Wang
Professor
Johns Hopkins University School of Medicine
Wenjun Fan
Assistant Professor
University of Maryland School of Medicine
Niladri Sinha
Assistant Professor
University of Utah
Ie-Ming Shih
Professor
Johns Hopkins University
Katherine B. Chiappinelli
George Washington University
Ronny Drapkin
Franklin Payne Professor of Pathology in Obstetrics and Gynecology
University of Pennsylvania
Robert B Scharpf
Associate Professor
Johns Hopkins University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.